ADAPTILENS ANNOUNCES $17.5M SERIES A FINANCING

Dr. Clamen featured in the When Science Speaks podcast

In the “When Science Speaks” podcast episode titled “Ophthalmology and Entrepreneurship with Liane Clamen, M.D.,” Dr. Clamen discusses her journey from practicing ophthalmology to founding Adaptilens, a company developing innovative intraocular lenses aimed at restoring the eye’s natural focusing ability. She shares insights into the challenges of transitioning from clinical practice to entrepreneurship, the importance of interdisciplinary collaboration, and the potential impact of advanced lens technology on patient outcomes.

Listen to the podcast

Updates
  • November 15, 2024

    Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.

    Read More
  • November 12, 2024

    We’re excited to share that Adaptilens has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for this nomination. We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. Read the full announcement here: https://lnkd.in/e548JKAk #NEVYsSurvivor #NEVCA #Innovation

  • October 19, 2024

    Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.

Follow Adaptilens on Linkedin

Adaptilens in the news

View all news
Adaptilens is made possible with help from​
notice: The Adaptilens is in the development phase and is not yet approved for investigational or commercial use.

Follow our progress on

Linkedin